“In aggregate, the data from the Brilacidin Phas
Post# of 72440
(Total Views: 317)
Posted On: 09/24/2018 1:48:33 PM
“In aggregate, the data from the Brilacidin Phase 2 study was impressive and we will consider expanding the drug to other cancer indications in the future,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “For now, we want to maintain our focus on the shortest path to commercialization, which we believe is best achieved by targeting treatment in the more aggressive chemotherapy regimens, in which cases of severe oral mucositis abound.”
BP will promote B-OM for the other cancer indications. It's what they do.
B-OM is going to be huge imo. Well past the initial billion $ market.
BP will promote B-OM for the other cancer indications. It's what they do.
B-OM is going to be huge imo. Well past the initial billion $ market.
(1)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼